Prof Ian Frazer Appointed to Scientific Advisory Board of Avantogen's Hawaii Biotech, Inc.
Dr William Ardrey, CEO of Avantogen commented, "The addition of Prof Ian Frazer to Hawaii Biotech is a very positive development for Avantogen's shareholders. His appointment is seen as a validation of the technology platform as well as of the vaccines that are currently in clinical development at HBI. Previously, shareholders have seen progress with the US FDA and the West Nile Virus program. The Dengue program in conjunction with the Paediatric Dengue Vaccines Initiative (PDVI), funded by the Bill & Melinda Gates Foundation and Rockefeller Foundation, is also running according to schedule. We hope to deliver progress reports on these programs in the coming weeks."
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.